Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Published:2016-10-06 Issue:12 Volume:65 Page:1533-1544
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Alva Ajjai,Daniels Gregory A.,Wong Michael K. K.,Kaufman Howard L.,Morse Michael A.,McDermott David F.,Clark Joseph I.,Agarwala Sanjiv S.,Miletello Gerald,Logan Theodore F.,Hauke Ralph J.,Curti Brendan,Kirkwood John M.,Gonzalez Rene,Amin Asim,Fishman Mayer,Agarwal Neeraj,Lowder James N.,Hua Hong,Aung Sandra,Dutcher Janice P.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1910-x.pdf

Reference32 articles.

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

2. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688–696

3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116

4. Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6(Suppl 1):S55–S57

5. Payne R, Glenn L, Hoen H, Richards B, Smith JW 2nd, Lufkin R, Crocenzi TS, Urba WJ, Curti BD (2014) Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer 2:2–13

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10

2. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics;Journal for ImmunoTherapy of Cancer;2024-04

3. The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma;Cancers;2024-01-28

4. Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice;Heliyon;2024-01

5. PEGylation Strategy for Improving the Pharmacokinetic and Antitumoral Activity of the IL-2 No-alpha Mutein;Current Pharmaceutical Design;2023-12